STAAR Surgical Visian ICL Sales surges
Ophthalmic products leader STAAR Surgical Company on Monday declared that sales of Visian ICL, an implantable contact lens, rose about 52 percent in the third quarter, primarily on the strength of greater international demand.
International sales of the ICL lens grew 65 percent as Visian ICL took a larger share of the market. Although laser vision correction procedures continued to decline in the U.S., STAAR said Visian revenue there increased 25 percent, which shows overall decline in the Lasik Surgery business and more and more people are opting for ICL than Lasik. ICL is treated as safe surgery to operate because you can correct the ICL surgery later, but Lasik if went wrong can’t be corrected. The risk is huge.
U.S. sales of the Visian lens have been relatively flat since the product was introduced, and totaled just over $1 million in the year-ago quarter. International sales were about $2.2 million.
The Visian lens is used to correct conditions including nearsightedness, farsightedness and astigmatism.
October 30th, 2008 at 11:50 pm
[...] that ICL is better than Lasik. The biggest Lasik/ICL manufacturer STARR VISION already noticing huge drop in Lasik sales and a tremendous pickup in ICL sales. Just a hint that Lasik is slowly becoming an old technology and ICL will soon become a primary eye [...]